NCT06577766

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

A Randomised, Placebo Controlled, Double Blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Single and Multiple Subcutaneous Doses of NNC0638-0355 in Participants With Overweight or Obesity

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	NNC0638-0355	NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
DRUG	Placebo (NNC0638-0355)	Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.

Timeline

• Start date: 2024-09-03
• Primary completion: 2026-09-24
• Completion: 2026-09-24
• First posted: 2024-08-29
• Last updated: 2026-03-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study